Former President Bill Clinton says the results of a clinical trial on CBD’s effectiveness in treating pain are “very encouraging” and stresses the importance of exploring alternatives to opioid-based pain relievers, according to a statement from press release from the company that supplied the cannabinoid for the study.
The former president, who famously admitted to using marijuana in his youth but denied inhaling it, appears to have been following the progress of cannabinoid trials at NYU Langone, which relied on products supplied by Orcosa that contained CBD provided by TR Processing (TRP). the latter company announced this Tuesday.
“The Clinton Foundation has worked for years to reduce opioid addiction and deaths,” Clinton said in a press release. “To be successful, we need non-addictive alternatives to pain management. The results of the trial conducted by NYU Langone, with TRP’s CBD ingredient, are very encouraging and I look forward to seeing the results of the next round.”
The results of the clinic trialinvolving 99 participants between the ages of 18 and 75 who underwent rotator cuff surgery, found that Orcosa’s ORAVEXX CBD tablet significantly reduced postoperative pain compared with placebo, with no effect serious secondary
Marihuana Moment reached out to the Clinton Foundation and the former president’s office for additional comment, but a representative was not immediately available.
The new statement about the results follows comments the former president made earlier this year, talking about emerging research into cannabidiol as an effective treatment that can help “fight pain.”
The article about her remarks was then deleted, allegedly related to pressure from the Clinton team, before being reposted online.
In any case, TRP also said Tuesday that a former deputy White House drug czar, Andrea Barthwell, has joined the company’s board of directors and will lead a division of the business dedicated to developing proprietary therapeutics. Barthwell has been abruptly criticized by defenders of previous disparaging and misleading claims he made about medical cannabis, suggesting it was snake oil before he helped GW Pharmaceuticals as they worked to get approval for the cannabinoid drug Sativex.
“I am excited about TRP’s focus on responsible cannabinoid development and believe that patients, physicians and pharmaceutical companies alike are looking for safe and effective solutions for pain management and overall health and wellness,” Barthwell said in the company Press release.
As for Clinton, her administration opposed efforts to legalize medical cannabis and even took the extreme step threatening to revoke the Drug Enforcement Administration’s (DEA) prescribing licenses for doctors who prescribed marijuana to patients under state law.
Furthermore, despite pleas to reduce the racial disparity in crack and cocaine sentencing, the former president took no action to address the problem. He also rejected requests to lift a federal ban on harm-reduction policies like syringe exchange programs.
However, in an exit interview published by Rolling Stone in 2000 just before leaving office, Clinton appeared to endorse cannabis reform, saying she thinks “most small amounts of marijuana have been decriminalized in some places and should be.”
Pennsylvania governor signs marijuana insurance and banking reform bill
Photographic element courtesy of Gage Skidmore.
Marijuana Moment is made possible with the support of readers. If you rely on our cannabis advocacy journalism to keep you informed, please consider a monthly Patreon pledge.